Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.30 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | LPL | P06858 | 1/20 | 0.30 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.30 |
| ▸ | MET | P08581 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13487275 | 0.92 | SIRT2 (0.34) | KDM4ECYP11B1CYP11B2CYP17A1CYP19A1 | |
| SCHEMBL13487178 | 0.91 | MCL1 (0.32) | — | |
| SCHEMBL13487111 | 0.90 | CYP17A1 (0.31) | CYP17A1 | |
| SCHEMBL13487359 | 0.89 | PDK2 (0.31) | — | |
| SCHEMBL13487664 | 0.88 | KDM4E (0.35) | KDM4EMAPK9MAPK10CYP11B1CYP11B2 | |
| SCHEMBL13487281 | 0.88 | MAPK9 (0.36) | KDM4EMAPK9MAPK10CYP11B1CYP11B2 | |
| SCHEMBL13488058 | 0.88 | KDM4E (0.34) | KDM4EMAPK9MAPK10CYP11B1CYP11B2 | |
| SCHEMBL13487311 | 0.86 | KDM4E (0.34) | KDM4ECYP11B1CYP11B2CYP17A1CYP19A1 | |
| SCHEMBL13487283 | 0.86 | PDK2 (0.37) | KDM4EMAPK9MAPK10CYP11B1CYP11B2 | |
| SCHEMBL13487277 | 0.85 | HSD17B1 (0.37) | KDM4EMAPK9MAPK10CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100045170-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-25 | — | — | US | disclosed |
| US-20100045170-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100045170-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | OCIAD1, OCIAD2, ORMDL3 | KDM4E 3671/4885MAPK9 1941/4885MAPK10 1970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.